The gain of function mutations in PIK3CA/AKT pathways, which are downstream of the HER2 receptor and are caused by a loss of the tumor suppressor PTEN, can confer resistance to HER2 inhibitors. This evidence concerns the gene ERBB2 and neoplasm.